Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED S CAN-002
CVAC TRIAL PUBLISHED IN JOURNAL
FOR IMMUNOTHERAPY OF CANCER
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today announced that a research article
titled A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. Dr. Paul
Mitchell is the lead author.
The research paper relates to the Company s CAN-002 clinical trial of CVac in 28 patients with advanced epithelial
ovarian cancer, completed in 2007. The clinical activity of CVac in ovarian cancer was evident from the CAN-002 data, based on decline or stabilization of CA125 in some patients. CVac was well tolerated by patients. The CAN-002 trial supported the
continued clinical development of CVac.
A full copy of the research article is available on the Journal for ImmunoTherapy of Cancer website:
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated
to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima s lead product is CVac an autologous dendritic cell-based product currently in clinical trials.
For further information please contact:
Adam Holdsworth, ProActive Capital
+1 (646) 862 4607; adamh@proactivecapital.com
Australia Investor/Media:
Mr Matthew Gregorowski,
Citadel Communications
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889